Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Keeps “Functional Equivalence” In 2004; Amgen Submits Aranesp Data

Executive Summary

Amgen has submitted data to the Centers for Medicare & Medicaid Services suggesting reimbursement for Aranesp should be increased by more than 50% in the final 2004 Hospital Outpatient Prospective Payment System rule

You may also be interested in...



Faslodex, Aranesp Have Special Status Under Hospital Payment Rule

CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005

Faslodex, Aranesp Have Special Status Under Hospital Payment Rule

CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005

Procrit, Aranesp Reimbursement Adjusted; CMS Splits The Difference

The new payment formula for J&J's Procrit (epoetin alfa) and Amgen's Aranesp (darbepoetin alfa) under the Medicare Hospital Outpatient Prospective Payment System reflects the ratio of dosing used by Medicare providers in chemotherapy patients, CMS said

Related Content

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel